Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results
康希諾生物製劑肺炎球菌疫苗的I期試驗取得積極成果
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊